-
Most Recent
Search Results
240 results for MER
Novavax Is Conducting Clinical Trials: The Ride In NVAX Stock Will Continue To Be Wild
NVAX stock has been among the hottest stocks in 2020, but it still remains a risky investment
Inovio Pharmaceuticals Is Hurting From Remdesivir but It’s Still Standing
With White House health advisor Dr. Anthony Fauci’s endorsement of Gilead Sciences’ remdesivir, INO stock now seems irrelevant. But that might not be accurate if…
Why Science and Economics Might Justify CureVac
Amid a sea of red ink in the Covid-19 vaccine space, CureVac stock has gone against the grain, printing some sizable gains. Can investors trust…
5 Weird Mutual Funds Worth Your Investment
Most mutual funds use some kind of industry-standard stock selection methodology. A few like to do their own thing. Here are four worth considering.
Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone
NVAX stock’s prospects in November depend upon regulatory developments regarding its Covid-19 vaccine candidate
As Optimism Wanes, the Ride May Be Over for Novavax stock
Novavax has been one of the companies cashing in on the race to find a vaccine against COVID-19. As a result NVAX stock is up…
Why June 30 Could Trigger a Private Credit Reckoning
Today, Louis is joining us to explain why a key deadline — June 30 — could force long-hidden problems into the open. That’s when certain…
Gilead Sciences Is a Strong Buy Despite What Its Detractors Might Say
Gilead Sciences is donating 1.5 million doses of remdesivir, which has many analysts bullish on GILD stock now.
I Would Hope Inovio Isn’t Attracting ANY Serious Money
A recent article wondered if the smart money preferred Ocugen or Inovio. I would hope neither INO stock or OCGN is getting any serious money.
Is Inovio Stock Still a Buy After Its Massive 150% Leap This Year?
Inovio is developing a potential vaccine for the coronavirus. If you can handle the volatility, it may be time to buy INO stock.
Germany Makes a $299 Million Bet on CureVac
CureVac recently was awarded $299 million to support the development of its Covid-19 vaccine. What does this mean for CureVac stock?
As Its Vaccine Dreams Fade, Inovio Stock Will Keep Retreating
INO stock has pulled back some 72% from its highs. But the fade makes sense, and even at a cheaper price the stock still looks…
5 Easy Ways to Throw PG Stock in Your Cart
PG stock has had a good year in 2013, but sometimes you’re better off with an ETF that holds the stock. Here are 5 ways…
Why June 30 Could Trigger a Private Credit Reckoning
Early in my career, I worked as a banking analyst. It was the 1980s, and the savings and loan crisis was in full swing. At…
Gilead Stock Isn’t Worth Chasing Now Despite Recent Remdesivir Success
Gilead’s remdesivir appears to be an effective treatment against the coronavirus. Still, I wouldn’t chase GILD stock now.
Beauty Stocks: 3 to Buy, 3 to Leave
This month has been wild for beauty shares. It’s time to turn to the Socratic principle: Question everything.
The InvestorPlace Q&A: Embrace the Food Revolution With the ANEW ETF
The ANEW ETF is investing in companies pushing the boundaries of technology when it comes to feeding the planet. Here’s what you need to know.
How TradeSmithGPT Can Turn Good Calls Into Great Ones
Complex systems designed to sniff out moves in the market have only gotten better with time. And now, we’re making our corporate partner TradeSmith’s most…
7 – 10 of 240 results
